JPMorgan Chase & Co. 13D and 13G filings for Revance Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-11 12:16 pm Purchase | 2024-12-31 | 13G | Revance Therapeutics, Inc. RVNC | JPMORGAN CHASE & CO JPM | 5,686,631 5.400% | 2,917,940 (+105.39%) | Filing |
| 2024-04-09 1:17 pm Sale | 2024-03-29 | 13G | Revance Therapeutics, Inc. RVNC | JPMORGAN CHASE & CO JPM | 2,768,691 2.600% | -1,986,080 (-41.77%) | Filing |
| 2024-01-25 11:11 am Unchanged | 2023-12-29 | 13G | Revance Therapeutics, Inc. RVNC | JPMORGAN CHASE & CO JPM | 4,754,771 5.400% | 0 (Unchanged) | Filing |
| 2024-01-25 11:10 am Sale | 2023-12-29 | 13G | Revance Therapeutics, Inc. RVNC | JPMORGAN CHASE & CO JPM | 4,754,771 5.400% | -228,178 (-4.58%) | Filing |
| 2023-01-27 12:22 pm Sale | 2022-12-30 | 13G | Revance Therapeutics, Inc. RVNC | JPMORGAN CHASE & CO JPM | 4,982,949 6.000% | -1,811,274 (-26.66%) | Filing |
| 2022-01-18 12:59 pm Purchase | 2021-12-31 | 13G | Revance Therapeutics, Inc. RVNC | JPMORGAN CHASE & CO JPM | 6,794,223 9.400% | 2,727,181 (+67.06%) | Filing |
| 2021-01-29 09:25 am Purchase | 2020-12-31 | 13G | Revance Therapeutics, Inc. RVNC | JPMORGAN CHASE & CO JPM | 4,067,042 6.100% | 38,545 (+0.96%) | Filing |